Literature DB >> 25797161

Novel 2-(2-phenalkyl)-1H-benzo[d]imidazoles as antitubercular agents. Synthesis, biological evaluation and structure-activity relationship.

Katarzyna Gobis1, Henryk Foks2, Karolina Suchan2, Ewa Augustynowicz-Kopeć3, Agnieszka Napiórkowska3, Krzysztof Bojanowski4.   

Abstract

A series of novel 2-(2-phenalkyl)-1H-benzo[d]imidazole derivatives and analogues (2a-3l) have been synthesized and evaluated for tuberculostatic activity. Benzimidazoles substituted at the C-2 position with phenethyl, styryl and 3,5-dichlorophenethyl moiety were obtained. Compounds 2g, 2h and 2i bearing methyl groups at the benzimidazole system and phenalkyl substituent at the C-2 position showed high tuberculostatic activity against Mycobacterium tuberculosis strains with MIC values ranging from 0.8 to 6.2 μg/mL (2.5-25 μM). More importantly, derivatives 2g (5,6-dimethyl-2-phenethyl-1H-benzo[d]imidazole) and 2i (2-(3,5-dichlorophenethyl)-5,6-dimethyl-1H-benzo[d]imidazole) appeared selective for M. tuberculosis as compared with eukaryotic cells: non-malignant (neonatal human dermal fibroblasts) and malignant (mouse melanoma B16-F10 cell line). These compounds may thus represent a novel, selective class of anti-tubercular agents. SAR studies resulted in interesting conclusions on structural factors affecting tuberculostatic activity.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Anti-proliferative activity; Benzimidazole; SAR-study; Synthesis; Tuberculostatic activity

Mesh:

Substances:

Year:  2015        PMID: 25797161     DOI: 10.1016/j.bmc.2015.03.008

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  7 in total

1.  1H-Benzo[d]Imidazole Derivatives Affect MmpL3 in Mycobacterium tuberculosis.

Authors:  Małgorzata Korycka-Machała; Albertus Viljoen; Jakub Pawełczyk; Paulina Borówka; Bożena Dziadek; Katarzyna Gobis; Anna Brzostek; Malwina Kawka; Mickael Blaise; Dominik Strapagiel; Laurent Kremer; Jarosław Dziadek
Journal:  Antimicrob Agents Chemother       Date:  2019-09-23       Impact factor: 5.191

2.  Discovery of newer pyrazole derivatives with potential anti-tubercular activity via 3D-QSAR based pharmacophore modelling, virtual screening, molecular docking and molecular dynamics simulation studies.

Authors:  Palmi Modi; Shivani Patel; Mahesh Chhabria
Journal:  Mol Divers       Date:  2022-08-15       Impact factor: 3.364

3.  Differences in the Structure and Antimicrobial Activity of Hydrazones Derived from Methyl 4-Phenylpicolinimidate.

Authors:  Katarzyna Gobis; Małgorzata Szczesio; Andrzej Olczak; Izabela Korona-Głowniak; Ewa Augustynowicz-Kopeć; Ida Mazernt-Politowicz; Dagmara Ziembicka; Marek L Główka
Journal:  Materials (Basel)       Date:  2022-04-24       Impact factor: 3.748

4.  3D QSAR-based design and liquid phase combinatorial synthesis of 1,2-disubstituted benzimidazole-5-carboxylic acid and 3-substituted-5H-benzimidazo[1,2-d][1,4]benzodiazepin-6(7H)-one derivatives as anti-mycobacterial agents.

Authors:  Nikum D Sitwala; Vivek K Vyas; Piyush Gedia; Kinjal Patel; Rania Bouzeyen; Saqib Kidwai; Ramandeep Singh; Manjunath D Ghate
Journal:  Medchemcomm       Date:  2019-03-22       Impact factor: 3.597

Review 5.  Pipeline of anti-Mycobacterium abscessus small molecules: Repurposable drugs and promising novel chemical entities.

Authors:  Anna Egorova; Mary Jackson; Victor Gavrilyuk; Vadim Makarov
Journal:  Med Res Rev       Date:  2021-03-01       Impact factor: 12.388

Review 6.  Advances in Drug Discovery of New Antitubercular Multidrug-Resistant Compounds.

Authors:  Guilherme Felipe Dos Santos Fernandes; Chung Man Chin; Jean Leandro Dos Santos
Journal:  Pharmaceuticals (Basel)       Date:  2017-06-01

7.  Synthesis and Tuberculostatic Activity Evaluation of Novel Benzazoles with Alkyl, Cycloalkyl or Pyridine Moiety.

Authors:  Malwina Krause; Henryk Foks; Ewa Augustynowicz-Kopeć; Agnieszka Napiórkowska; Małgorzata Szczesio; Katarzyna Gobis
Journal:  Molecules       Date:  2018-04-23       Impact factor: 4.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.